Try a new search

Format these results:

Searched for:



Total Results:


HIV gp120-V2 loop costimulation in presence of retinoic acid promotes HIV infection of CD4+T cells [Meeting Abstract]

Goes, L. Ramos; Sajani, A.; Nawaz, F.; Van Ryk, D.; Yolitz, J.; Wei, D.; Mason, R.; Roederer, M.; Kong, X.; Morris, L.; Cicala, C.; Fauci, A. S.; Arthos, J.
ISSN: 1758-2652
CID: 4829632

Antiretroviral Imprints and Genomic Plasticity of HIV-1 pol in Non-clade B: Implications for Treatment

Bimela, Jude S; Nanfack, Aubin J; Yang, Pengpeng; Dai, Shaoxing; Kong, Xiang-Peng; Torimiro, Judith N; Duerr, Ralf
Combinational antiretroviral therapy (cART) is the most effective tool to prevent and control HIV-1 infection without an effective vaccine. However, HIV-1 drug resistance mutations (DRMs) and naturally occurring polymorphisms (NOPs) can abrogate cART efficacy. Here, we aimed to characterize the HIV-1 pol mutation landscape in Cameroon, where highly diverse HIV clades circulate, and identify novel treatment-associated mutations that can potentially affect cART efficacy. More than 8,000 functional Cameroonian HIV-1 pol sequences from 1987 to 2020 were studied for DRMs and NOPs. Site-specific amino acid frequencies and quaternary structural features were determined and compared between periods before (≤2003) and after (2004-2020) regional implementation of cART. cART usage in Cameroon induced deep mutation imprints in reverse transcriptase (RT) and to a lower extent in protease (PR) and integrase (IN), according to their relative usage. In the predominant circulating recombinant form (CRF) 02_AG (CRF02_AG), 27 canonical DRMs and 29 NOPs significantly increased or decreased in RT during cART scale-up, whereas in IN, no DRM and only seven NOPs significantly changed. The profound genomic imprints and higher prevalence of DRMs in RT compared to PR and IN mirror the dominant use of reverse transcriptase inhibitors (RTIs) in sub-Saharan Africa and the predominantly integrase strand transfer inhibitor (InSTI)-naïve study population. Our results support the potential of InSTIs for antiretroviral treatment in Cameroon; however, close surveillance of IN mutations will be required to identify emerging resistance patterns, as observed in RT and PR. Population-wide genomic analyses help reveal the presence of selective pressures and viral adaptation processes to guide strategies to bypass resistance and reinstate effective treatment.
PMID: 35222310
ISSN: 1664-302x
CID: 5174032

Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes

Upadhyay, Chitra; Feyznezhad, Roya; Cao, Liwei; Chan, Kun-Wei; Liu, Kevin; Yang, Weiming; Zhang, Hui; Yolitz, Jason; Arthos, James; Nadas, Arthur; Kong, Xiang-Peng; Zolla-Pazner, Susan; Hioe, Catarina E
HIV-1 envelope (Env) is a trimer of gp120-gp41 heterodimers, synthesized from a precursor gp160 that contains an ER-targeting signal peptide (SP) at its amino-terminus. Each trimer is swathed by ~90 N-linked glycans, comprising complex-type and oligomannose-type glycans, which play an important role in determining virus sensitivity to neutralizing antibodies. We previously examined the effects of single point SP mutations on Env properties and functions. Here, we aimed to understand the impact of the SP diversity on glycosylation of virus-derived Env and virus neutralization by swapping SPs. Analyses of site-specific glycans revealed that SP swapping altered Env glycan content and occupancy on multiple N-linked glycosites, including conserved N156 and N160 glycans in the V1V2 region at the Env trimer apex and N88 at the trimer base. Virus neutralization was also affected, especially by antibodies against V1V2, V3, and gp41. Likewise, SP swaps affected the recognition of soluble and cell-associated Env by antibodies targeting distinct V1V2 configurations, V3 crown, and gp41 epitopes. These data highlight the contribution of SP sequence diversity in shaping the Env glycan content and its impact on the configuration and accessibility of V1V2 and other Env epitopes.
PMID: 33370382
ISSN: 1553-7374
CID: 4731662

Priming with DNA expressing trimeric HIV V1V2 alters the immune hierarchy favoring the development of V2-specific antibodies in rhesus macaques

Devasundaram, Santhi; Rosati, Margherita; Valentin, Antonio; Weiss, Svenja; Itri, Vincenza; Trinh, Hung V; Bear, Jenifer; Chowdhury, Bhabadeb; LaBranche, Celia C; Montefiori, David; Ferrari, Guido; Rao, Mangala; Kong, Xiang-Peng; Zolla-Pazner, Susan; Pavlakis, George N; Felber, Barbara K
The RV144 vaccine trial revealed a correlation between reduced risk of HIV infection and the level of non-neutralizing antibody (Ab) responses targeting specific epitopes in the second variable domain (V2) of the HIV gp120 envelope (Env) protein, suggesting this region as a target for vaccine development. To favor induction of V2-specific Abs, we developed a vaccine regimen that included priming with DNA expressing an HIV V1V2 trimeric scaffold immunogen followed by booster immunizations with a combination of DNA and protein in rhesus macaques. Priming vaccination with DNA expressing the HIV recombinant subtype CRF01_AE V1V2 scaffold induced higher and broader V2-specific Ab responses than vaccination with DNA expressing CRF01_AE gp145 Env. Abs recognizing the V2 peptide that was reported as a critical target in RV144 developed only after the priming immunization with V1V2 DNA. The V2-specific Abs showed several non-neutralizing Fc-mediated functions, including ADCP and C1q binding. Importantly, robust V2-specific Abs were maintained upon boosting with gp145 DNA and gp120 protein co-immunization. In conclusion, priming with DNA expressing the trimeric V1V2 scaffold alters the hierarchy of humoral immune responses to V2 region epitopes, providing a method for more efficient induction and maintenance of V2-specific Env Abs associated with reduced risk of HIV infection.IMPORTANCE The aim of this work has been to design and test a vaccine regimen focusing the immune response to targets associated with infection prevention. We demonstrated that priming with a DNA vaccine expressing only the HIV Env V1V2 region induces Ab responses targeting the critical region in V2 associated with protection. This work shows that V1V2 scaffold DNA priming immunization provides a method to focus immune responses to the desired target region, in the absence of immune interference by other epitopes. This induced immune responses with improved recognition of epitopes important for protective immunity, namely, V2-specific humoral immune responses inversely correlating with HIV risk of infection in the RV144 trial.
PMID: 33087466
ISSN: 1098-5514
CID: 4642832

An HIV vaccine targeting the V2 region of Envelope induces a highly durable polyfunctional Fc-mediated antibody response in rhesus macaques

Powell, Rebecca L; Weiss, Svenja; Fox, Alisa; Liu, Xiaomei; Itri, Vincenza; Jiang, Xunqing; Luo, Christina C; Spencer, David A; Pandey, Shilpi; Cheever, Tracy; Fuller, Deborah H; Totrov, Maxim; Hessell, Ann J; Haigwood, Nancy L; Kong, Xiang-Peng; Zolla-Pazner, Susan
The HIV vaccine field now recognizes the potential importance of generating polyfunctional antibodies (Abs). The only clinical HIV vaccine trial to date to show significant efficacy (RV144) found that reduced infection rates correlated with the level of non-neutralizing Abs specific for the V2 region of the envelope glycoprotein. We have conducted a comprehensive preclinical reverse vaccinology-based vaccine program that has included the design and production and testing of numerous scaffolded V2 region immunogens. The most immunogenic vaccine regimen in nonhuman primates among those studied as part of this program consisted of a cocktail of three immunogens presenting V2 from different viruses and clades in the context of different scaffolds. Presently we demonstrate that the V2-specific Ab response from this regimen is highly durable and functionally diverse for the duration of the study (25 weeks after the final immunization). The total IgG binding response at this late time point exhibited only ∼5x reduction in potency. Three immunizations appeared essential for the elicitation of a strong Ab-dependent cellular cytotoxicity (ADCC) response for all animals, as opposed to the Ab-dependent cellular phagocytosis (ADCP) and virus capture responses, which were comparably potent after only 2 immunizations. All functionalities measured were highly durable through the study period. Therefore, testing this vaccine candidate for its protective capacity is warranted.Importance The only HIV vaccine trial for which protective efficacy was detected correlated this efficacy with V2-specific Abs that were effectively non-neutralizing. This result has fueled a decade of HIV vaccine research focused on designing an HIV vaccine capable of eliciting V2-focused, polyfunctional Abs that effectively bind HIV and trigger various leukocytes to kill the virus and restrict viral spread. From the numerous vaccine candidates designed and tested as part of our V2-focused preclinical vaccine program, we have identified immunogens and a vaccine regimen that induces a highly durable and polyfunctional V2-focused Ab response in rhesus macaques, described herein.
PMID: 32554699
ISSN: 1098-5514
CID: 4496792

VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA

Jia, Manxue; Liberatore, Rachel A; Guo, Yicheng; Chan, Kun-Wei; Pan, Ruimin; Lu, Hong; Waltari, Eric; Mittler, Eva; Chandran, Kartik; Finzi, Andrés; Kaufmann, Daniel E; Seaman, Michael S; Ho, David D; Shapiro, Lawrence; Sheng, Zizhang; Kong, Xiang-Peng; Bieniasz, Paul D; Wu, Xueling
The HIV-1 envelope (Env) undergoes conformational changes during infection. Broadly neutralizing antibodies (bNAbs) are typically isolated by using soluble Env trimers, which do not capture all Env states. To address these limitations, we devised a vesicular stomatitis virus (VSV)-based probe to display membrane-embedded Env trimers and isolated five bNAbs from two chronically infected donors, M4008 and M1214. Donor B cell receptor (BCR) repertoires identified two bNAb lineages, M4008_N1 and M1214_N1, that class-switched to immunoglobulin G (IgG) and IgA. Variants of these bNAbs reconstituted as IgA demonstrated broadly neutralizing activity, and the IgA fraction of M1214 plasma conferred neutralization. M4008_N1 epitope mapping revealed a glycan-independent V3 epitope conferring tier 2 virus neutralization. A 4.86-Ã…-resolution cryogenic electron microscopy (cryo-EM) structure of M1214_N1 complexed with CH505 SOSIP revealed another elongated epitope, the V2V5 corridor, extending from V2 to V5. Overall, the VSVENV probe identified bNAb lineages with neutralizing IgG and IgA members targeting distinct sites of HIV-1 Env vulnerability.
PMID: 32315598
ISSN: 1934-6069
CID: 4402202

The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals

Philips, Elliot A; Garcia-España, Antonio; Tocheva, Anna S; Ahearn, Ian M; Adam, Kieran R; Pan, Ruimin; Mor, Adam; Kong, Xiang-Peng
Programmed cell death protein 1 (PD-1) is an inhibitory receptor on T lymphocytes that is critical for modulating adaptive immunity. As such, it has been successfully exploited for cancer immunotherapy. Programmed death ligand 1 (PD-L1) and PD-L2 are ligands for PD-1; the former is ubiquitously expressed in inflamed tissues, whereas the latter is restricted to antigen-presenting cells (APCs). PD-L2 binds to PD-1 with 3-fold stronger affinity compared to PD-L1. To date, this affinity discrepancy has been attributed to a tryptophan (W110PD-L2) that is unique to PD-L2 and has been assumed to fit snuggly into a pocket on the PD-1 surface. Contrary to this model, using surface plasmon resonance (SPR) to monitor real-time binding of recombinantly expressed and purified proteins, we found that W110PD-L2 acts as an "elbow" that helps shorten PD-L2 engagement with PD-1 and therefore lower affinity. Further, we identified a "latch" between the C and D β strands of the binding face as the source of the PD-L2 affinity advantage. We show that the 3-fold affinity advantage of PD-L2 is the consequence of these two opposing features, the W110PD-L2 "elbow" and a C-D region "latch." Interestingly, using phylogenetic analysis, we found that these features evolved simultaneously upon the emergence of placental mammals, suggesting that PD-L2-affinity tuning was part of the alterations to the adaptive immune system required for placental gestation.
PMID: 31882544
ISSN: 1083-351x
CID: 4244482

Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses

Hessell, Ann J; Powell, Rebecca; Jiang, Xunqing; Luo, Christina; Weiss, Svenja; Dussupt, Vincent; Itri, Vincenza; Fox, Alisa; Shapiro, Mariya B; Pandey, Shilpi; Cheever, Tracy; Fuller, Deborah H; Park, Byung; Krebs, Shelly J; Totrov, Maxim; Haigwood, Nancy L; Kong, Xiang-Peng; Zolla-Pazner, Susan
The V1V2 region of the HIV-1 envelope is the target of several broadly neutralizing antibodies (bNAbs). Antibodies to V1V2 elicited in the RV144 clinical trial correlated with a reduced risk of HIV infection, but these antibodies were without broad neutralizing activity. Antibodies targeting V1V2 also correlated with a reduced viral load in immunized macaques challenged with simian immunodeficiency virus (SIV) or simian/human immunodeficiency virus (SHIV). To focus immune responses on V1V2, we engrafted the native, glycosylated V1V2 domain onto five different multimeric scaffold proteins and conducted comparative immunogenicity studies in macaques. Vaccinated macaques developed high titers of plasma and mucosal antibodies that targeted structurally distinct V1V2 epitopes. Plasma antibodies displayed limited neutralizing activity but were functionally active for ADCC and phagocytosis, which was detectable 1-2 years after immunizations ended. This study demonstrates that multivalent, glycosylated V1V2-scaffold protein immunogens focus the antibody response on V1V2 and are differentially effective at inducing polyfunctional antibodies with characteristics associated with protection.
PMID: 31340151
ISSN: 2211-1247
CID: 3988102

Author Correction: The wide utility of rabbits as models of human diseases

Esteves, Pedro J; Abrantes, Joana; Baldauf, Hanna-Mari; BenMohamed, Lbachir; Chen, Yuxing; Christensen, Neil; González-Gallego, Javier; Giacani, Lorenzo; Hu, Jiafen; Kaplan, Gilla; Keppler, Oliver T; Knight, Katherine L; Kong, Xiang-Peng; Lanning, Dennis K; Le Pendu, Jacques; de Matos, Ana Lemos; Liu, Jia; Liu, Shuying; Lopes, Ana M; Lu, Shan; Lukehart, Sheila; Manabe, Yukari C; Neves, Fabiana; McFadden, Grant; Pan, Ruimin; Peng, Xuwen; de Sousa-Pereira, Patricia; Pinheiro, Ana; Rahman, Masmudur; Ruvoën-Clouet, Natalie; Subbian, Selvakumar; Tuñón, Maria Jesús; van der Loo, Wessel; Vaine, Michael; Via, Laura E; Wang, Shixia; Mage, Rose
This article was originally published under a CC BY-NC-SA License, but has now been made available under a CC BY 4.0 License.
PMID: 31270317
ISSN: 2092-6413
CID: 3968232

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV

Zolla-Pazner, Susan; Alvarez, Raymond; Kong, Xiang-Peng; Weiss, Svenja
PURPOSE OF REVIEW/OBJECTIVE:In humans, only one independent immunologic correlate of reduced risk of HIV infection has been identified: a robust antibody (Ab) response to the V1V2 domain of the gp120 envelope (Env) protein. In recent years, the presence and level of V1V2-specific Abs has also been correlated with protection from SIV and SHIV infections. Here, we review the multitude of studies showing the in-vivo protective effects of V1V2 Abs and review their immunologic characteristics and antiviral functions. RECENT FINDINGS/RESULTS:Structural and immunologic studies have defined four epitope families in the V1V2 domain: one epitope family, V2q, which preferentially presents as a quaternary structure of the Env trimer, and another epitope family (V2qt) which requires the quaternary trimeric Env structure; these two epitope types are recognized by two families of monoclonal Abs (mAbs)-V2q-specific and V2qt-specific mAbs-which display broad and potent neutralizing activity. A third epitope family, V2i, is present as a discontinuous conformational structure that overlays the α4β7 integrin binding motif, and a fourth epitope family (V2p) exists on V2 peptides. Antibodies specific for V2i and V2p epitopes display only poor neutralizing activity but effectively mediate other antiviral activities and have been correlated with control of and/or protection from HIV, SIV and SHIV. Notably, V2q and V2qt Abs have not been induced by any vaccines, but V2p and V2i Abs have been readily induced with various vaccines in nonhuman primates and humans. SUMMARY/CONCLUSIONS:The correlation of vaccine-induced V2p and V2i Abs with protection from HIV, SIV and SHIV suggests that these Ab types are extremely important to induce with prophylactic vaccines.
PMID: 30994501
ISSN: 1746-6318
CID: 3810562